Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
01
01
2019
accepted:
09
04
2019
pubmed:
23
4
2019
medline:
8
2
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
Mastocytosis is characterized by the accumulation/proliferation of abnormal mast cells. The frequency of isolated cutaneous involvement in adults with mastocytosis has not been fully determined. The main objective of our study was to assess the frequency of isolated cutaneous mastocytosis (CM) in adults with mastocytosis skin lesions. The second objective was to compare the clinical, histological, biological and imaging features in patients with isolated CM and patients with systemic mastocytosis (SM). We included all patients with histology-proven mastocytosis skin lesions between January 2009 and December 2017. The mastocytosis diagnosis was made according to the international diagnostic criteria. All data were collected from a dedicated specific case report. Among 160 patients with mastocytosis skin lesions, 25 patients had isolated CM (15.6%), 105 had SM and 30 (18.7%) patients had undetermined mastocytosis. Skin KIT mutation (OR: 51.9, 95% CI: 3.9-678, P = 0.001) and high bone marrow tryptase (OR: 97.4, 95% CI: 10.3-915, P = 0.001) were strong predictors of SM. The prevalence of osteoporosis was higher in the SM population than in the isolated CM population. Moreover, a decrease in bone mineral density over a short period of follow-up (1-2 years) was associated with SM. There were no differences between the two groups regarding the frequency of mast cell activation symptoms, the presentation of skin lesions, the number of mast cells in the dermis and the level of serum tryptase. We propose considering the KIT mutation status and bone marrow tryptase levels to aid the diagnosis of isolated CM in adult mastocytosis patients. Only a small minority of adults with mastocytosis skin lesions has isolated cutaneous involvement. In 18.7% of mastocytosis cases, even complete workup does not allow for a precise classification of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Mastocytosis is characterized by the accumulation/proliferation of abnormal mast cells. The frequency of isolated cutaneous involvement in adults with mastocytosis has not been fully determined. The main objective of our study was to assess the frequency of isolated cutaneous mastocytosis (CM) in adults with mastocytosis skin lesions. The second objective was to compare the clinical, histological, biological and imaging features in patients with isolated CM and patients with systemic mastocytosis (SM).
METHODS
METHODS
We included all patients with histology-proven mastocytosis skin lesions between January 2009 and December 2017. The mastocytosis diagnosis was made according to the international diagnostic criteria. All data were collected from a dedicated specific case report.
RESULTS
RESULTS
Among 160 patients with mastocytosis skin lesions, 25 patients had isolated CM (15.6%), 105 had SM and 30 (18.7%) patients had undetermined mastocytosis. Skin KIT mutation (OR: 51.9, 95% CI: 3.9-678, P = 0.001) and high bone marrow tryptase (OR: 97.4, 95% CI: 10.3-915, P = 0.001) were strong predictors of SM. The prevalence of osteoporosis was higher in the SM population than in the isolated CM population. Moreover, a decrease in bone mineral density over a short period of follow-up (1-2 years) was associated with SM. There were no differences between the two groups regarding the frequency of mast cell activation symptoms, the presentation of skin lesions, the number of mast cells in the dermis and the level of serum tryptase. We propose considering the KIT mutation status and bone marrow tryptase levels to aid the diagnosis of isolated CM in adult mastocytosis patients.
CONCLUSION
CONCLUSIONS
Only a small minority of adults with mastocytosis skin lesions has isolated cutaneous involvement. In 18.7% of mastocytosis cases, even complete workup does not allow for a precise classification of patients.
Substances chimiques
Biomarkers
0
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Tryptases
EC 3.4.21.59
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1713-1718Informations de copyright
© 2019 European Academy of Dermatology and Venereology.
Références
Valent P, Sperr W, Schwartz L, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3-11.
Komi DEA, Rambasek T, Wöhrl S. Mastocytosis: from a molecular point of view. Clin Rev Allergy Immunol 2018; 54: 397-411.
Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001; 25: 519-528.
Valent P, Akin C, Hartmann K et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res 2017; 77: 1261-1270.
Pardanani A. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. Am J Hematol 2016; 91: 1146-1159.
Carter MC, Clayton ST, Komarow HD et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol 2015; 136: 1673-1679.e3.
Valent P, Akin C, Escribano L et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3ed, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008; 42: 467-475.
Horny HP, Akin C, Metcalfe DD et al. Mastocytosis (mast cell disease). In Swerdlow SH, Campo E, Harris NL (eds). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 2008: 54-63.
Valent P, Horny HP, Li CY et al. Mastocytosis. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 2001: 291-302.
Hartmann K, Escribano L, Grattan C et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2016; 137: 35-45.
Ackerman AB. Urticaria pigmentosa. In Ackerman AB ed. Histologic Diagnosis of Inflammatory Skin Diseases. An Algorithmic Method based on Pattern Analysis, 2nd éd. Baltimore: Williams & Wilkins, Philadelphia, PA, 1997: 877-881.
Lanternier F, Cohen-Akenine A, Palmerini F et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 2008; 3: e1906.
Degboé Y, Eischen M, Nigon D et al. Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone 2017; 105: 219-225.
El Maghraoui A, Do Santos Zounon AA, Jroundi I et al. Reproducibility of bone mineral density measurements using dual X-ray absorptiometry in daily clinical practice. Osteoporos Int 2005; 16: 1742-1748.
Barete S, Assous N, De Gennes C et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69: 1838-1841.
Bulai Livideanu C, Apoil PA, Lepage B et al. Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. Clin Exp Allergy 2016; 46: 133-141.
Van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012; 67: 431-438.
Bhullar H, Martyres R, Nicholls K, Varigos G, Douglas J, Saracino A. Mastocytosis: a case series of 107 consecutive patients. Br J Dermatol 2018; 178: e28-e29.
Merante S, Ferretti V, Elena C et al. The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncol 2018; 14: 2713-2723.
Valent P, Arock M, Bischoff SC et al. The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr 2004; 116: 647-651.
Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 2012; 157: 399-405.
Hermine O, Lortholary O, Leventhal PS et al. Case-control cohort study of patients’ perceptions of disability in mastocytosis. PLoS ONE 2008; 3: e2266.